We’re continuing our mini-series on cracking the ‘glyco-code’ with an interview with Dr Lieping Chen (Yale), one of the world’s leading cancer immunologists, someone who has taken basic science and translated it into a spin-off company, NextCure (NASDAQ: NXTC) and a new product (NC318) targeting Siglec-15 that’s already being evaluated in the clinic.

Will upregulation of Siglec-15 turn out to be key in some cancer patients?

What happens if you identify a novel target that is expressed in a subset of patients that’s key to resetting the immune response and overcoming the immuno-suppressive tumor microenvironment (TME)?

Not only that, but you can potentially use a biomarker to select the patients most likely to benefit from what we’re calling a ‘targeted immunotherapy’ that’s directed at overcoming a specific immune dysfunction or defect.

Think of it as like when you press the factory re-set button on your iPad or iPhone.

Over the course of the coming year, we expect to hear a lot more about the early clinical data for this novel approach so in this expert interview we’re talking to the founder about the science that’s propelling NextCure forward.

To learn more from out latest oncology expert interview and get a heads up on their candid perspectives, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by